Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Epirubicin|DRUG: Docetaxel
Sponsor: Hellenic Oncology Research Group
Collaborators: University Hospital of Crete